Status:
COMPLETED
CP-481,715 Nickel Allergy Study.
Lead Sponsor:
Pfizer
Conditions:
Dermatitis, Allergic Contact
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
To evaluate the suitability of contact allergy as a method for the evaluation of c-chemokine receptor-1 antagonist.
Eligibility Criteria
Inclusion
- A history of nickel allergy confirmed by a visual positive reaction (graded at least ++) to T.R.U.E. TEST.
Exclusion
- Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding contact allergic dermatitis or untreated, asymptomatic, seasonal allergies at time of dosing).
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
End Date :
October 1 2005
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00141180
Start Date
September 1 2003
End Date
October 1 2005
Last Update
July 25 2006
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48109-0314
2
Pfizer Investigational Site
New York, New York, United States, 10032
3
Pfizer Investigational Site
Austin, Texas, United States, 78759
4
Pfizer Investigational Site
Bryan, Texas, United States, 77802